MIRA Pharmaceuticals (MIRA) risk factors
Item 1A of every MIRA Pharmaceuticals, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors65 risks9 new6 dropped9 reworded
MIRA expanded its risk factors around the SKNY acquisition and licensing of SKNY-1 from MIRALOGX. Clinical trial risks now highlight the novel nature of synthetic cannabinoids and ketamine analogs. Nasdaq listing compliance replaced general share dilution risks.
Filed Mar 31, 2026 - FY2024 10-K risk factors62 risks
MIRA Pharmaceuticals faces substantial going concern doubt with an accumulated deficit of $29.1 million as of December 31, 2024. The company depends entirely on the success of pre-clinical candidates Ketamir-2 and MIRA-55. Operations rely heavily on third-party contractors for manufacturing and clinical trials.
Filed Mar 28, 2025